FDA Approves First Treatment for Metastatic Breast Cancer With Germline BRCA-MutationNalleyCatlin
Today, the FDA also expanded the approval of the BRACAnalysis CDx, an approved companion diagnostic to Lynparza, to include the detection of BRCA mutations in blood samples from patients with breast cancer. The safety and efficacy of Lynparza for the treatment of breast ...
For many years, tamoxifen was the mainstay of treatment for hormone receptor-positive metastatic breast cancer (MBC). However, in recent years, newer endocrine agents, particularly aromatase inhibitors, have consistently proved their superiority over tamoxifen by improving clinical outcomes. These agents...
Hatem Soliman, MD, discusses the current first-line treatment options for patients with HER2-positive breast cancer.
The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006; 11: 42-51.Gelmon K, Chan A, Harbeck N (2006) The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 11(Suppl 1):42–51 View ...
Bevacizumab, a recombinant humanised monoclonal antibody against vascular endothelial growth factor, is approved in Europe as first-line therapy for metast... X Pivot - 《Drugs》 被引量: 115发表: 2007年 Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? Metastatic breast ca...
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. Clin. Breast ......
Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. PURPOSE: We compared prospectively the antitumor efficacy of two combination chemotherapy regimens with two different dose levels of epirubicin as first-line treatment for ...
BACKGROUND: The prognosis for breast cancer patients overexpressing human epidermal growth factor receptor (HER)-2 has changed with anti-HER-2-targeted therapy. Although anti-HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to...
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study PURPOSE: To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as...